SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about disclosure

30 May 2025 Evaluate
Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

247.65 -1.95 (-0.78%)
16-Jun-2026 11:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.20
Dr. Reddys Lab 1278.30
Cipla 1383.80
Zydus Lifesciences 1081.00
Lupin 2267.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: